Succès de l’introduction en Bourse de Crossject sur Alternext

Back

Paris – 20 February  2014 EnterNext, the Euronext subsidiary designed to promote and grow its market for SMEs, today congratulated Crossject on its successful listing on Alternext in Paris

Dijon-based Crossject makes ZENEO®, an innovative, patented medical device for self-injection of medications. The product of 12 years of R&D with leading European partners, ZENEO® is unique in offering a needle-free, single-use, automatic, pre-filled device that improves patient safety and comfort. This new device is designed to gradually replace existing self-injection systems such as pen injectors and pre-filled syringes and open up new markets where no self-injection solutions are currently available.

Crossject (ticker symbol: ALCJ) was listed through the admission to trading of 4,204,831 existing shares making up the company’s equity and the sale of 2,034,615 new shares issued under a Global Offering[1], including full exercise of the extension option and exercise of the over-allotment option. Total demand was €56.3 million, including a €40 million Global Placement and a €16.3 million Open Price Public Offering. The offer was oversubscribed 4.4 times.

The admission and issue price of Crossject shares was set at €8.38 per share, at the high end of the indicative price range. The company’s market capitalisation stood at around €52.3 million on the issue date, and a total €17 million was raised altogether.

“I want to congratulate Crossject for its very successful listing on Alternext in Paris,” said Eric Forest, Chairman and CEO of EnterNext.“Crossject is an innovative company that has won over a broad range of investors, both institutions and individuals. At EnterNext, we are delighted to be part of the process as it moves into the market and in so doing help contribute its development.”

Patrick Alexandre, Crossject founder and head of its Executive Board said: “Our listing on Alternext is an important step for our company, and we would like to thank all our investors, old and new, for taking part. Its success means we are now in a position to take ZENEO® through the regulatory process for two indications with a view to putting it on the market at the end of 2015, and pursue business development at Crossject.”


[1]The Global Offering was made up of a Public Offering that included an Open Price Public Offering and a Global Placement with institutional investors in France and other countries.

Press Release Footer

About Euronext 
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With close to 2,000 listed issuers and around €5.8 trillion in market capitalisation as of end June 2022, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.  
For the latest news, follow us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).

Disclaimer
This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

© 2022, Euronext N.V. - All rights reserved.